Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Nov 24;25(2):e46–e54. doi: 10.1016/j.bbmt.2018.11.021

Table 1.

Evidence-based rating system used in this review

Category Definition
Strength of the Recommendation
A Should always be offered.
B Should generally be offered.
C Evidence for efficacy is insufficient to support a recommendation for or against, or evidence for efficacy might not outweigh adverse consequences, or cost of the approach. Optional.
D Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered.
E Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
Quality of Evidence Supporting the Recommendation
I Evidence from at least one properly randomized, controlled trial.
II Evidence for at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferable from more than one center) or from multiple time-series or dramatic results from uncontrolled experiments.
III Evidence from opinions of respected authorities based on clinical experience, descriptive.